Eric Dein ericdeinmd
4 years 3 months ago
#EULAR2022 OP0136:
PROTECT-RA Cohort - 150 pts established RA
Cholesterol loading capacity (CLC) on macrophages
⭐️High CLC correlates with CV events
⭐️bDMARD use affects CLC
@RheumNow https://t.co/9ngaH9yUI7
David Liew drdavidliew
4 years 3 months ago
Mortality after PMR:
looking at 35y follow-up of a cohort in Norway,
apparent higher mortality for women (vs men, general population) decades after.
Is this real? Treatment related?
My wild guess: sarcopenia kills.
Thoughts @Sarah_L_Mackie & tagged?
OP0181 #EULAR2022 @RheumNow https://t.co/k7p9jNfW5s
Md Yuzaiful Md Yusof Yuz6Yusof
4 years 3 months ago
#OP0144 #EULAR2022 Promising Digital use in monitoring disease activity for clinicians. Researchers in Amsterdam developed the first e-health #SLE T2T. High acceptance rate re: usability. Need more validation and in different languages @RheumNow https://t.co/7LravXhoJ8
David Liew drdavidliew
4 years 3 months ago
Sometimes hear “GCA associated with PMR is extracranial”
Interesting point:
of the 20% of PMR patients with USS-evident subclinical GCA
- one-quarter had isolated cranial disease
GCA phenotypes not so clear cut
(Proviso: it’s subclinical disease)
OP0184 #EULAR2022 @RheumNow https://t.co/storHFL8aW
Richard Conway RichardPAConway
4 years 3 months ago
Farshad et al. 17% of admissions on long-term allopurinol had it held. Reasons - acute gout flare, renal impairment, gastrointestinal issues, cytopenia, drug interactions, NPO status, and always discontinued the medication. @RheumNow #EULAR2022 OP0169 https://t.co/ADOomiOrRi https://t.co/nxAAOMWsJB
Aurelie Najm AurelieRheumo
4 years 3 months ago
RABBIT registry and MACE in RA
No difference between
*JAKi (Tofa and Bari) and *TNFi in both unselected and high CV risks patients.
🧨 different than ORAL surveillance
but Observational and overall Low incidence (28 events).
#EULAR2022 @RheumNow OP0135 https://t.co/o8rngHrwQF
Janet Pope Janetbirdope
4 years 3 months ago
#ClinicalPearl #SLE has ⬆️mortality until v advanced age and if not in remission or v low disease activity Mortality is higher. Ideas: control disease activity, prevent damage, limit prednisone. @RheumNow #EULAR2022 T Dormer Session #Lupus https://t.co/90cpsBVgAb
Richard Conway RichardPAConway
4 years 3 months ago
Rahman et al. Pooled safety data from IL23i guselkumab clinical trial programme in PsA. 1508 patients 2125 PY. No increase (and generally lower) than PBO. No IBD. @RheumNow #EULAR2022 POS1015 https://t.co/9otcpwW9ni
Md Yuzaiful Md Yusof Yuz6Yusof
4 years 3 months ago
#OP0141 #EULAR2022 What do our #lupus patients think about Treat-to-target (T2T) and are they involved? A patient survey showed improvement in QoL as most important. They were open to T2T concept but concerned of more visits + new drugs. 61% felt they were involved @RheumNow https://t.co/rT500lhrih
Dr. Antoni Chan synovialjoints
4 years 3 months ago
Rahman et al shows factors associated with variability of fatigue in PsA are systemic disease 34%, joint disease 16%, skin involvement 12%, accounting for 62% and leaving a residual effeect of 38% that was unexplained and needing further research #EULAR2022 @RheumNow OP0025 https://t.co/RoqjS64Xjy
Dr. Antoni Chan synovialjoints
4 years 3 months ago
The CONSUL study @ProftDr showed there was no significant difference in Celecoxib(CEL)+Golimumab (GOL) vs GOL alone. The mSASSS change was 1.1 vs 1.7, p=0.79 between the 2 groups. The combination may be clinically relevant in high-risk progressors #EULAR2022 @RheumNow OP0018 https://t.co/AUOL7IDx9L
It’s good to be back into full, big meeting mode.
Highlights included a EULAR Recommendation Session, where updated guidelines were presented for the management of a) ANCA-associated Vasculitis, b) ASAS/EULAR recommendations for axSpA and c) RA. Here are a few of my favorites from Day 1.
